Celcuity reports phase 1b prostate cancer trial results

Celcuity reported Phase 1b/2 results for gedatolisib plus darolutamide in 45 patients with metastatic castration-resistant prostate cancer. Median radiographic progression-free survival was 15.7 months for patients previously treated with abiraterone and 9.1 months for those previously treated with enzalutamide; PSA decreases of at least 50% ranged from 36% to 67% across dose levels. The company reported no Grade 4 or 5 treatment-related adverse events, discontinuations, or deaths due to adverse events, and expects to begin the Phase 2 portion in the first half of 2027.

Analysis

The signal is encouraging but not yet decision-grade efficacy evidence: this is a small, uncontrolled early-stage study, and the 240 mg dose-level PSA response comes from only seven patients. The reported rPFS differences by prior therapy may reflect patient mix or selection as much as treatment effect; reconcile the 40 patients in those two prior-treatment subgroups with total enrollment and verify follow-up, censoring, and response-evaluation methods. Tolerability is a positive development signal, but rash/pruritus and the intravenous schedule remain relevant to real-world use.

For CELC, the key value driver is whether a controlled Phase 2 can reproduce clinically meaningful benefit in patients progressing after androgen-receptor therapies—not the headline subgroup medians. Competition includes established post-ARPI options such as taxanes and, for eligible patients, PSMA-targeted radioligand therapy; a new combination must show enough benefit and tolerability to change treatment sequencing. Near term, the data may support sentiment, but the stated Phase 2 start is not until H1 2027, leaving a substantial catalyst gap. Over the next 6–18 months, financing runway, enrollment pace, protocol design, and a credible comparator matter as much as these early results. No valuation, consensus, or cash-runway data are provided, so avoid assuming the news is mispriced.

Key Decisions for Investors

• Do not chase CELC solely on these data. Treat as a watch-list catalyst: consider exposure only after reviewing the full congress presentation, patient-level follow-up and subgroup definitions, and the Phase 2 design.
• If already long, retain only a risk-sized event-driven position; the upside case is confirmation in Phase 2, while the downside is that the uncontrolled signal does not reproduce or the program is delayed. Check cash runway and potential financing needs before adding.
• Monitor the Phase 2 start and enrollment timeline, dose selection, independent efficacy assessment, and rates of dose interruption or discontinuation. A missed H1 2027 start or weaker controlled efficacy would falsify the near-term thesis; durable benefit with manageable toxicity would strengthen it.